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Abstract
Purpose PET/CT with the PSMA ligand is a powerful new
method for the early detection of nodal metastases in patients
with biochemical relapse. The purpose of this retrospective
investigation was to evaluate the volume and dimensions of
nodes identified by Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)]
(68Ga-PSMA-11) in the setting of recurrent prostate cancer.
Methods All PET/CT images were acquired 60±10 min after
intravenous injection of 68Ga-PSMA-11 (mean dose
176 MBq). In 21 patients with recurrent prostate cancer and
rising PSA, 49 PSMA-positive lymph nodes were identified.
Using semiautomated lymph node segmentation software,
node volume and short-axis and long-axis dimensions were
measured and compared with the maximum standardized up-
take values (SUVmax). Round nodes greater than or equal to
8 mm were considered positive by morphological criteria
alone. The percentage of nodes identified by elevated
SUVmax but not by conventional morphological criteria
was determined.
Results The mean volume of 68Ga-PSMA-11-positive nodes
was 0.5 ml (range 0.2 – 2.3 ml), and the mean short-axis
diameter was 5.8 mm (range 2.4 – 13.3 mm). In 7 patients
(33.3 %) with 31 PSMA-positive nodes only 11 (36 %) were
morphologically positive based on diameters >8 mm on CT.
In the remaining 14 patients (66.7 %), 18 (37 %) of PSMA
positive lymph nodes had short-axis diameters <8 mm with a
mean short-axis diameter of 5.0 mm (range 2.4 – 7.9 mm).
Thus, in this population, 68Ga-PSMA-11 PET/CT detected
nodal recurrence in two-thirds of patients who would have
been missed using conventional morphological criteria.
Conclusion 68Ga-PSMA-11 PET/CT is more sensitive than
CT based 3D volumetric lymph node evaluation in determin-
ing the node status of patients with recurrent prostate cancer,
and is a promising method of restaging prostate cancers in this
setting.
Keywords 68Ga-PSMA-11 PET/CT . Recurrent prostate
cancer . Lymph node evaluation . Lymph nodemetastasis
Introduction
The pelvic lymph nodes are a common site of recurrent pros-
tate cancer after surgery or radiation. Evidence based largely
on the levels of prostate-specific antigen (PSA) in biochemical
recurrence indicate that the sooner treatment, typically
consisting of radiation and androgen deprivation therapy
(ADT), is instituted after detection, the better is survival [1].
This increases the importance of early detection and localiza-
tion of recurrent disease, whether in the lymph nodes or in the
prostatic bed (Figs. 1, 2, 3 and 4).
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Fig. 1 A 67-year-old patient with
recurrent prostate cancer after
prostatectomy. a The 68Ga-PSMA
PET maximum intensity
projection demonstrates multiple
positive nodes in the pelvis
abdomen, thorax and neck. b–d
The CT image (b), PET/CT image
(c) and PET image (d) show a
single axial slice in the pelvis
demonstrating three PSMA-
positive nodes (arrows)
Fig. 2 Image processing of a PSMA-positive node. The node
corresponding to the positive 68Ga-PSMA PET images (a, d SUVmax
5.82) is represented on the CT images (b axial, c coronal, and f sagittal
planes). It was segmented using Fraunhofer MEVIS software enabling
automated quantification of the dimensions (short-axis diameter
4.19 mm, long-axis diameter 6.76 mm). e Volume rendering of the
segmented node also provided by the software
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Current methods for assessing lymph nodes in the recur-
rence setting are limited. Although pelvic lymph node dissec-
tion is considered the most reliable procedure for assessing the
presence of nodal invasion in the primary setting, this is often
impractical in the recurrence setting [2]. CT is commonly used
for nodal staging. However, CT has a limited ability to predict
lymph node invasion because of its low sensitivity for small-
volume or micrometastatic disease [3–5]. In order to avoid
excessive false-positive findings, the normal upper limit of
the short-axis diameter of pelvic lymph nodes is usually set
at 7 – 10 mm depending on the location. However, up to 80%
of metastatic lymph nodes in prostate cancer have a short-axis
diameter less than 7 mm [3–6]. Similar comments apply to
MRI which has classically relied on size criteria alone, al-
though there has been recent interest in the use of diffusion-
weighted MRI in this setting [7]. Thus, morphological criteria
alone are highly limited in their ability to predict lymph node
recurrence.
A new imaging method, PSMA PET/CT, has recently been
introduced to evaluate prostate cancer. Prostate-specific mem-
brane antigen (PSMA) is highly expressed in many prostate
cancers and correlates with traditional negative prognostic
factors such as a high Gleason score, metastasis or recurrent
disease, but is not found in most other tissues [8]. Thus
Fig. 3 Volume (a), short-axis diameter (b) and long-axis diameter (c) of PSMA positive lymph nodes indicating that 68Ga-PSMA PET/CT is able to
detect many metastatic nodes smaller than the standard size for positive lymph nodes on CT or MRI (diameter >1 cm, volume >0.5 cm3)
Fig. 4 Morphological
distribution of all 49 PSMA-
positive lymph nodes in terms of
their short-axis diameter (a) and
long-axis diameter (c). The
relationships between SUVmax
and the short axis diameter (b)
and long axis diameter (d) of the
PSMA-positive lymph nodes are
also shown
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PSMA-targeted PET agents have considerably more specific-
ity than conventional anatomic imaging. However, it is not
clear that PET/CT with the 68Ga-PSMA ligand has superior
sensitivity to CT alone, given the lower spatial resolution of
PET in comparison with CT. For instance, typical PET scan-
ners have a spatial resolution of 3 – 5 mm, whereas CT has
submillimetre resolution, and it might be that only larger
nodes are detectable by PET.
Therefore, we aimed to determine if PET/CT with 68Ga-
PSMA-11 is capable of detecting nodal metastases below the
conventional CT size thresholds for nodal metastasis.
Materials and methods
Patients
In this retrospective investigation we evaluated a total of 49
PET-positive lymph nodes in 21 consecutive patients (median
age 70 years, range 54–79 years) referred to radiooncology
with biochemical recurrence (i.e. rising PSA) of prostate can-
cer following radical prostatectomy (initial mean PSA level
6.84 ng/ml, range 0.6 – 45 ng/ml). The patients included in
this investigation had a mean Gleason score of 8 (range 6 – 9).
All patients the D’Amico risk category was intermediate or
high at diagnosis (Table 1). All patients signed a written in-
formed consent form for the purposes of anonymized evalua-
tion and publication of their data. All reported investigations
were conducted in accordance with the principles of the
Declaration of Helsinki and with our national regulations.
This evaluation was approved by the Ethics Committee of
the University of Heidelberg.
Image acquisition, PSMA PET analysis and volumetric
CT histogram analysis
All PET/CTexaminations were done on a Biograph 6 PET/CT
scanner (Siemens/CTI). Imaging was started 60±10 min after
intravenous injection of 68Ga-PSMA-11 at a median dose of
176MBq (range 79 – 317MBq). For attenuation correction of
the PET scan, a CT scan (130 keV, 80 mAs; CareDose) with-
out contrast medium was performed. Static emission scans,
corrected for dead time, scatter and decay, were acquired from
the vertex to the proximal legs, requiring eight bed positions
with 3 min per bed position. The images were iteratively re-
constructed with the OSEM algorithm using four iterations
with eight subsets and Gaussian filtering to an in-plane spatial
resolution of 5 mm at full-width at half-maximum. For calcu-
lation of the standardized uptake value (SUV), circular regions
of interest were drawn around the area with focally increased
uptake in transaxial slices and automatically adapted to a
three-dimensional volume of interest with e.soft software
(Siemens) at a 70 % isocontour. The CT scan was
reconstructed with a B30 kernel to a slice thickness of 5 mm
with an increment of 2.5 mm. Lymph nodes were considered
PSMA-positive when the maximum SUV (SUVmax) was >2.
This cut-off value was chosen after evaluating the blood pool
at 60 min after injection in the aorta, which was found to have
a mean±standard deviation SUVmax of 1.49±0.49.
Volumetric CT analysis was performed on PET-positive
nodes using semiautomated software (Fraunhofer MEVIS,
Bremen, Germany) that segments the nodes and automatically
determines mean density, short-axis diameter, long-axis diam-
eter and volume. Semiautomatic three-dimensional histogram
analysis is initiated after the user provided a seed point in the
lymph node and the software found the margins of the node.
The segmentation starts with a fixed-width thresholding
around the seed point. To remove attached vessels, muscles
or other lymph nodes, a watershed transform is performed on
the distance map of the thresholding result. The watershed
transform is controlled by include and exclude markers which
are set according to an ellipsoid approximation of the lymph
node. The volumes were evaluated by a radiologist to ensure
that no extraneous tissue was segmented and manually
corrected in all three dimensions, if necessary.
Statistical evaluation
Nodes with a diameter more than 8 mm were accepted as
positive for metastasis on CT [9, 10]. Descriptive statistics
defining the percent positive PET/CT scans with nodes small-
er than the above size criteria were calculated. Pearson coef-
ficients were calculated using Excel (Microsoft, Seattle, WA).
Results
A total of 49 lymph nodes in 21 patients could clearly be
correlated with nodal uptake on 68Ga-PSMA ligand PET/
CT. By study definition all 49 lymph nodes demonstrated
68Ga-PSMA ligand uptake on PET/CT with a mean
SUVmax of 7.43 (range 1.8 – 25.2). Among the 49 PSMA-
positive lymph nodes, 38 (78 %) were morphologically neg-
ative (<8 mm) and 11 (22 %) were morphologically positive
on conventional imaging (≥8 mm) (Fig. 4). All 49 lymph
nodes were analysed with the semiautomated segmentation
software. Semiautomatic segmentation required less than
5 min per patient but enabled derivation of several important
parameters: lymph-node size (short and long axis) and lymph-
node volume. The interobserver and intraobserver reproduc-
ibility was good with a coefficient of variation <5 % when the
software was evaluated for reliability in a recent study [11].
The mean volume of all 49 lymph nodes was 0.5 ml (range
0.2 – 2.3 ml), the mean short-axis diameter was 5.8 mm (range
2.4 – 13.3 mm) and the mean long axis diameter was 9.5 mm
(range 4.7 – 19.3 mm). In seven patients (33 %) at least one
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node was larger than the conventional criteria for morpholog-
ical positivity. However, among the 31 PSMA-positive nodes
in these patients only 11 (36 %) were ≥8 mm on the CT scan
with a mean short-axis diameter of 11.8 mm (range
8.4 – 19.1 mm). None of 14 patients (67 %) with 18 PSMA-
positive lymph nodes met the morphological criteria for pos-
itivity. In this group, the mean short-axis diameter was 5.0 mm
(range 2.4 – 7.9 mm) and the mean PSMA SUVmax was 5.5
(range 1.8 – 13.1). Thus, the N stage was changed from N0 to
N1 in 14 of 21 patients (67 %) in this cohort on 68Ga-PSMA
ligand PET/CT.
Discussion
PSA testing after surgery or radiation therapy for prostate
cancer permits the early identification of patients with bio-
chemical recurrence. There is evidence that early treatment
may result in better outcomes [1]. However, localization of
the site of recurrence has proven to be difficult and thus em-
pirical therapies such as pelvic irradiation and ADT have been
employed. However, such treatments are given without spe-
cific regard to the location of the recurrence. Localizing the
exact sites of recurrence could permit a more targeted ap-
proach with fewer side effects. In patients with single lesions
surgery with curative intent may be performed although this is
controversial. Other options include targeted ablation, focal
radiation and even molecular and immunomodulatory thera-
pies. Missing from the current clinical decision tree, however,
is an effective means of detecting and monitoring recurrence
sites while this Btherapeutic window^ is still open.
A common site of recurrent disease in prostate cancer is the
pelvic lymph nodes. However, the existing methods for detec-
tion of nodes such as CTorMRI are nonspecific. Enlargement
of round nodes beyond 8 mm is considered a positive finding
with a low sensitivity of approximately 34 – 40 % and a
moderate/high specificity (80 – 97%) [9, 10, 12]. Just as small
nodes below the size threshold are commonly missed, large
lymph nodes above the size threshold may simply represent
nodal hyperplasia. For this reason, CT and MRI are not con-
sidered reliable enough for routine nodal staging [2]. A source
of considerable error in studies of lymph nodes is the variabil-
ity in the manual measurement of lymph node size.
Volumetric analysis allows a more precise and objective as-
sessment of tumour burden. It was first introduced for pulmo-
nary nodules and recently was made clinically available with
special software packages [13]. CT volumetric analysis soft-
ware (Fraunhofer MEVIS) was used to precisely determine
nodal volume. This enabled reliable and rapid nodal measure-
ments in this study.
As reported recently, enhanced uptake of 68Ga-PSMA-11
correlated well with the surgical pathology in 42 patients [14].
Table 1 Patient demographics






Risk (d'Amico category) SUVmax
1 54 5.6 6 High 8.7
2 75 2.7 7 Intermediate 6.2
3 75 10.6 8 High 4.9
4 65 1.6 7 Intermediate 4.5
5 79 3.1 9 High 3.1
6 78 2.7 9 High 4.9
7 75 3.8 7 Intermediate 6.9
8 70 2.33 8 High 12.1
9 71 2.77 7 Intermediate 13.1
10 70 7.2 9 High 6.7
11 71 1.4 8 High 2.4
12 69 5.88 7 Intermediate 3.14
13 62 1.35 9 High 3.8
14 59 45 7 Intermediate 25.2
15 63 0.62 6 Intermediate 4.3
16 72 12 9 High 15.5
17 69 0.8 7 Intermediate 4.3
18 78 1.8 7 Intermediate 9.8
19 55 6.4 8 High 8.9
20 63 25.4 8 High 5.6
21 68 0.64 7 High 1.8
1798 Eur J Nucl Med Mol Imaging (2015) 42:1794–1800
In 319 patients evaluated with follow-up as the standard of
reference, sensitivity and specificity were found to be 76.6 %
and 100 %, and the negative and positive predictive values
were 91.4 % and 100 %, respectively [14]. Due to the positive
predictive value of 100 % in this large study with a thoroughly
defined gold standard, a positive PSMA PETwas considered
as the standard of reference for lymph node involvement in
our investigation. Nevertheless, PSMA is not specific for
prostate cancer but can also be found in the neovasculature
of other solid tumours (thyroid, colon, kidney, glioblastoma).
Thus, false-positive lymph node metastases can occur in pa-
tients with secondary malignancies. Nevertheless, the likeli-
hood that PSMA-positive lymph nodes found in the typical
lymph drainage region of the prostate are true-positive can be
considered to be close to 100 %. In our small patient popula-
tion we did not observe PET-positive lymph nodes in uncom-
mon locations, which would have to be interpreted more cau-
tiously with regard to the possibility of a second malignancy.
In this analysis, 21 patients with recurrent prostate cancer
who underwent 68Ga-PSMA-11 PET/CT were evaluated.
Among the 21 patients, only 7 (33 %) harboured nodes that
exceeded the size criterion for metastases on CT. This is con-
sistent with existing data on the sensitivity of CT. However,
the remaining 14 patients who were considered normal by CT
criteria were actually shown to harbour metastases in small
nodes not meeting the size criterion for positivity on CT.
Further, only 11 (22.45 %) of the 49 PSMA-positive nodes
met the size criterion for metastasis on CT. Thus, using stan-
dard TNM staging only one-third of the patients in this study
would have been considered cN1 by CT criteria. The use of
PSMA PET/CT imaging led to the reclassification of another
14 patients from cN0 to cN1. In a previous study evaluating
patients with prostate cancer prior to first-line radiotherapy,
68Ga-PSMA-11 PET/CT led to a change in TNM staging
due to a change from cN0 to cN1 in nearly 40 % of patients.
This result is in line with the results of our current investiga-
tion [15].
In the past, other PET imaging tracers have also been used
in the setting of biochemical recurrence. 11C-Choline is one
such agent that has shown variable success in this setting [13,
16, 17]. Other PET tracers include 18F-fluoromethyl choline
(18F-FMCh), 18F-fluoroethyl choline (18F-FECh), 11C-acetate,
18F-FACBC (radiofluorinated aminocyclobutane carboxylic
acid) and 18F-FDHT (radiofluorinated dihydrotestosterone),
but none has emerged as clearly superior to any other. Our
initial experience with 68Ga-PSMA-11 PET/CT suggests that
this novel tracer can detect relapses and metastases with high
contrast by binding to the extracellular catalytic domain of
PSMA, followed by internalization [18, 19].
A significant advantage of PSMA PET/CT is that PSMA-
11 uptake in lymph node and other soft tissue metastases is
higher than that of other agents [19–21]. Another promising
recently introduced PSMA ligand labelled with 18F showed
similar contrast ratios in a small cohort of seven patients [22].
A potential disadvantage is that tumoral PSMA expression
may be modulated by the androgen receptor. In preclinical
studies based on cell lines, antiandrogens initially upregulated
PSMA expression [22] while prolonged ADT seemed to
downregulate PSMA over time [23, 24] but might also induce
upregulation after ADT is withdrawn [14]. In contrast, 68Ga-
PSMA-11 PET/CT was more frequently positive in patients
receiving ADT at the time of the scan than in patients without
such treatment [25]. Thus further clinical studies are necessary
to draw a final conclusion on the impact of ADT on the ex-
pression of tumour PSMA in humans.
Conclusion
In this study, two-thirds of patients with recurrent prostate
cancer were upstaged from cN0 to cN1 based on their 68Ga-
PSMA-11 PET/CTscan. The majority (78 %) of nodes detect-
ed by 68Ga-PSMA-11 PET/CT were smaller than 8 mm in
diameter and therefore did not meet standardized morpholog-
ical criteria for metastatic nodes. Thus, 68Ga-PSMA-11 PET/
CT appears to be a promising method of restaging patients
with suspected recurrent prostate cancer based on elevated
PSA levels. The ability of 68Ga-PSMA-11 PET/CT to detect
focal sites of disease in recurrent prostate cancer with high
sensitivity opens the possibility for early targeted therapies.
In the case of single lesions, a surgical approach may be con-
sidered, although data are currently sparse. Other options in-
clude targeted ablative technologies or focal radiation. Further
investigations are necessary to demonstrate which of these
treatment modalities can really benefit from improved diag-
nostic sensitivity.
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